Source:http://linkedlifedata.com/resource/pubmed/id/21293287
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2011-2-10
|
| pubmed:abstractText |
PARP, poly (adenosine diphosphate-ribose) polymerase, is a damage-sensing protein, which is essential for the repair of DNA single-strand breaks. PARP and p53 function synergistically in repairing DNA damage and suppressing chromosomal rearrangements. The aim of this study was to determine the expression of PARP and p53 in epithelial ovarian cancer (EOC) and to correlate their expression with clinicopathologic characteristics. PARP and p53 were evaluated using immunohistochemistry applied on a tissue microarray of 189 EOC and their expressions were correlated to clinicopathologic variables, including the age of diagnosis, stage, grade, histologic type, optimal debulking, progression-free survival, and overall survival (OS). PARP and p53 expressions were shown in 61% and 54% of cases, respectively. PARP-positive tumors are more likely to have higher grade (P=0.03) and complete response to initial first-line chemotherapy (P=0.009). Patients with positive p53 staining are more likely to be at the advanced stage disease (P=0.004). Finally, there were no significant associations between PARP and p53 expression and no differences in progression-free survival and OS for PARP or p53 expressions. The overexpression of PARP and p53 in high grade, and advanced stage tumors indicated that these 2 markers might serve as an indicator of aggressive disease behavior. Additional studies are warranted to evaluate the role of PARP and PARP inhibitors in the setting of adjuvant chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1538-7151
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
30
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
139-44
|
| pubmed:meshHeading |
pubmed-meshheading:21293287-Adult,
pubmed-meshheading:21293287-Aged,
pubmed-meshheading:21293287-Aged, 80 and over,
pubmed-meshheading:21293287-Disease-Free Survival,
pubmed-meshheading:21293287-Female,
pubmed-meshheading:21293287-Humans,
pubmed-meshheading:21293287-Immunohistochemistry,
pubmed-meshheading:21293287-Kaplan-Meier Estimate,
pubmed-meshheading:21293287-Middle Aged,
pubmed-meshheading:21293287-Neoplasm Staging,
pubmed-meshheading:21293287-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:21293287-Ovarian Neoplasms,
pubmed-meshheading:21293287-Poly(ADP-ribose) Polymerases,
pubmed-meshheading:21293287-Prognosis,
pubmed-meshheading:21293287-Tissue Array Analysis,
pubmed-meshheading:21293287-Treatment Outcome,
pubmed-meshheading:21293287-Tumor Markers, Biological,
pubmed-meshheading:21293287-Tumor Suppressor Protein p53
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
|
| pubmed:affiliation |
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. heidi.godoy@roswellpark.org
|
| pubmed:publicationType |
Journal Article
|